worldwid
communityacquir
pneumonia
cap
one
frequent
infecti
diseas
lead
caus
death
sever
studi
shown
pathogen
could
identifi
patient
although
children
month
infecti
agent
detect
viral
infect
frequent
children
year
wherea
bacteri
infect
increas
age
rsv
influenzavirus
rhinovirus
parainfluenzavirus
adenovirus
common
virus
associ
cap
children
among
adenovirus
predomin
adenoviru
report
sever
countri
emerg
highli
pathogen
variant
signific
lethal
young
children
mani
childhood
respiratori
infect
caus
one
pathogen
mix
viral
bacteri
infect
observ
cap
immunocompet
adult
rare
wherea
person
underlay
diseas
increas
incid
cap
elderli
rsv
influenzavirus
parainfluenzavirus
less
frequent
adenovirus
predomin
virus
caus
pneumonia
less
frequent
associ
cap
newli
discov
human
metapneumoviru
coronavirus
hantavirus
involv
hantaviru
pulmonari
syndrom
belong
emerg
pathogen
date
north
middl
south
america
optimum
diagnosi
whole
spectrum
potenti
respiratori
viral
agent
includ
multipl
diagnost
techniqu
use
view
high
relev
influenzaviru
cap
influenza
vaccin
highli
advis
prevent
cap
especi
highrisk
group
viral
infect
involv
cap
frequent
mix
infect
viralvir
viralbacteri
detect
cap
infant
young
children
commonli
due
viral
infect
predomin
respiratori
syncyti
viru
rsv
develop
countri
incid
viral
pneumonia
higher
relev
reason
death
young
children
major
viral
pathogen
summar
tabl
usual
caus
mild
selflimit
ill
mainli
restrict
upper
respiratori
tract
lead
viral
pathogen
sever
diseas
rsv
influenzavirus
past
two
decad
new
mostli
zoonot
viral
pathogen
emerg
like
sarscoronaviru
avian
influenzavirus
hantavirus
associ
hantaviru
pulmonari
syndrom
hp
cross
speci
barrier
numer
virus
occasion
caus
sever
respiratori
diseas
lower
respiratori
tract
better
known
clinic
manifest
tab
respiratori
viru
infect
common
winter
earli
spring
caus
respiratori
ill
without
clear
season
pattern
frequenc
detect
respiratori
virus
vari
differ
studi
due
methodolog
problem
mani
studi
includ
known
respiratori
virus
addit
preval
virus
may
vari
time
differ
geograph
area
immunocompromis
patient
exogen
respiratori
virus
may
persist
prolong
shed
individu
subclin
infect
may
undetect
sourc
transmiss
studi
investig
respiratori
virus
asymptomat
human
variabl
result
agedepend
occurr
asymptomat
respiratori
infect
report
highest
frequenc
young
children
newborn
year
virusassoci
cap
occur
mainli
infant
young
children
elderli
frail
adult
person
underli
diseas
immunocompromis
patient
even
harmless
agent
like
rhinoor
coronavirus
frequent
induc
acut
disord
exacerb
peopl
chronic
cardiopulmonari
diseas
asthma
main
host
environ
relat
risk
factor
investig
influenc
variou
factor
predispos
cap
controversi
gener
viralassoci
cap
decreas
age
sever
recent
studi
develop
countri
pathogen
detect
immunocompet
children
cap
patient
evid
singl
viral
infect
viralvir
infect
viralbacteri
infect
inflamm
diseas
sever
viralbacteri
infect
nonimmunocompromis
adult
demonstr
viral
etiolog
less
common
roux
et
al
identifi
pathogen
case
proport
viral
infect
approxim
singl
viral
infect
influenzaviru
frequent
identifi
viral
agent
studi
chronic
heart
failur
chf
risk
factor
viru
infect
viru
compos
nonenvelop
icosahedr
particl
contain
doublestrand
linear
dna
genom
nm
diamet
consist
capsom
hexon
penton
filament
glycoprotein
fiber
penton
base
display
characterist
differ
length
human
adenovirus
classifi
six
speci
subgen
era
af
basi
antigen
biolog
properti
hemagglutin
tumorogen
anim
quit
good
agreement
classif
base
genom
differ
like
dna
homolog
less
virus
differ
subgenera
serotypespecif
epitop
predominantli
found
hexon
capsomer
termin
part
fiber
defin
quantit
neutral
test
present
serotyp
identifi
neutral
antibodi
nine
document
respiratori
pathogen
adenovirus
resist
also
proteolyt
enzym
intestin
tract
speci
c
adenovirus
endem
respons
approxim
human
adenoviru
infect
adv
adenoviru
infect
commonli
adv
earli
life
wherea
caus
symptomat
lower
respiratori
tract
infect
primari
infect
c
virus
may
shed
fece
month
even
year
follow
initi
infect
c
virus
establish
lifelong
asymptomat
persist
infect
current
unknown
state
viral
persist
probabl
place
persist
tonsil
adenoid
new
data
suggest
human
mucos
tlymphocyt
may
harbor
c
adenovirus
latent
form
prematur
infant
high
risk
develop
dissemin
neonat
adenoviru
infect
pneumonia
high
lethal
infant
children
adenoviru
infect
primarili
occur
month
year
respons
childhood
pneumonia
outbreak
predominantli
healthi
children
frequent
associ
type
follow
type
adv
children
high
risk
mortal
rate
healthi
children
adv
differ
abil
induc
inflammatori
respons
lung
tissu
particularli
adv
involv
sever
lung
inflamm
neutrophil
infiltr
incid
adv
infect
may
vari
depend
detect
assay
studi
popul
gener
higher
children
adult
describ
case
viral
coinfect
recogn
like
adv
infect
caus
also
reactiv
endogen
viru
infect
link
season
pattern
adenoviru
epidem
occur
human
popul
live
crowd
condit
poor
hygien
larg
outbreak
predominantli
caus
type
observ
recruit
us
militari
nineti
percent
advinfect
person
develop
pneumonia
vaccin
adv
sinc
effect
reduc
ill
serotyp
recent
epidemiolog
studi
shown
latent
subgroup
c
virus
involv
chronic
diseas
immmunocompet
patient
high
risk
pneumonia
induc
viral
pathogen
dissemin
adenoviru
infect
difficult
treat
agent
use
ribavirin
cidofovir
yield
variabl
result
benefit
intraven
ribavirin
synthet
guanosin
analog
treatment
lifethreaten
diseas
especi
immunocompromis
patient
seem
better
antivir
therapi
start
earli
report
could
show
clear
benefici
effect
vivo
well
vitro
data
suggest
suscept
ribavirin
highli
depend
viru
speci
virus
subgroup
c
shown
sensit
ribavirin
wherea
serotyp
subgroup
b
e
f
resist
despit
high
level
long
treatment
patient
chang
sensit
viru
isol
ribavirin
date
report
cidofovir
nucleotid
analogu
cytosin
effect
vitro
activ
differ
dna
virus
adenovirus
includ
treatment
indic
sever
dissemin
adv
infect
result
vari
treatment
limit
sever
nephrotox
emerg
resist
adv
observ
experiment
system
coronavirus
spheric
pleomorph
envelop
virus
diamet
nm
possess
largest
genom
rna
virus
singlestrand
posit
rna
associ
nucleoprotein
n
form
helic
nucleoprotein
complex
surround
envelop
contain
three
characterist
surfac
structur
protein
membran
protein
envelop
protein
e
oligomer
protein
form
spike
virion
surfac
resembl
solar
corona
protein
determin
cell
tropism
respons
pathogen
strongest
induc
neutral
antibodi
coro
navirus
contain
fourth
envelop
protein
hemagglutin
esteras
activ
four
serogroup
distinguish
contain
three
human
pathogen
group
prototyp
group
known
sever
acut
respiratori
syndrom
sar
led
detect
novel
coronaviru
consecut
extens
research
field
led
discoveri
coronavirus
see
follow
rhinovirus
coronavirus
frequent
associ
common
cold
young
adult
seem
pose
risk
healthi
elderli
non
sar
coronavirus
rare
caus
pneumonia
howev
may
caus
diseas
lower
respiratori
tract
lrt
infant
immunocompromis
patient
patient
underli
diseas
frail
older
adult
endem
outbreak
elderli
patient
risk
rare
develop
pneumonia
first
describ
netherland
although
widespread
within
human
popul
seldom
respons
pneumonia
children
recent
novel
coronaviru
patient
copd
pneumonia
describ
hong
kong
pneumonia
far
describ
occur
winter
spring
predominantli
elderli
year
comorbid
novemb
new
emerg
diseas
sar
describ
china
contagi
potenti
lethal
atyp
pneumonia
sarscov
origin
anim
virus
could
result
recombin
mammalian
avian
coronavirus
june
worldwid
case
ill
countri
regist
death
lethal
sarscov
seem
distinct
cell
entri
pathway
initi
infect
possibl
extrem
low
infecti
dose
result
gener
proteas
lung
respons
effici
rate
infect
younger
children
sar
often
induc
rel
mild
nonspecif
respiratori
ill
chines
studi
overal
mortal
rate
increas
patient
group
seriou
underli
diseas
therapi
resist
inform
antivir
treatment
hcov
infect
rare
case
hcov
associ
pneumonia
present
also
standard
antivir
therapi
recommend
sar
ribavirin
corticosteroid
use
sever
ill
patient
seem
effect
better
outcom
report
combin
therapi
lopinavirritonavir
ribavirin
plu
steroid
noth
known
emerg
resist
viru
variant
human
avian
influenzavirus
describ
separ
chapter
within
book
epidemiolog
associ
cap
virolog
diagnosi
discuss
chapter
children
year
adult
comorbid
predominantli
chronic
heart
diseas
bronchopulmonari
dysplasia
pregnant
women
second
third
trimest
person
year
high
risk
influenza
virusassoci
pneumonia
use
sensit
method
shown
preval
influenza
infect
older
children
cap
may
higher
mix
infect
mostli
viralbacteri
infect
document
influenza
virusassoci
pneumonia
pregnanc
accompani
higher
morbid
lethal
infant
may
born
preterm
low
weight
although
pneumonia
elderli
patient
may
present
respiratori
sign
recoveri
prolong
especi
frail
elderli
incid
pneumonia
highest
mix
infect
common
older
age
group
singl
viru
infect
seen
increasingli
patient
year
influenza
b
virusassoci
pneumonia
rare
report
singl
case
children
hpiv
pleomorph
envelop
virus
nm
contain
helic
nucleocapsid
singlestrand
neg
rna
encod
least
six
structur
protein
two
nonstructur
protein
import
two
envelop
glycoprotein
hn
hemagglutininneuraminidas
f
fusion
respons
neutral
antibodi
within
famili
paramyxovirus
hpiv
express
neuraminidas
activ
four
major
hpiv
serotyp
exist
divid
subtyp
genotyp
steadili
occur
antigen
variat
type
distribut
worldwid
type
predominantli
spread
america
four
serotyp
distinct
epidemiolog
clinic
behavior
hpiv
endem
throughout
year
yearli
epidem
outbreak
winter
spring
hpiv
associ
biennial
epidem
pattern
peak
fall
winter
parainfluenzavirus
particularli
type
seem
highest
virul
capac
persist
major
type
infect
occur
children
second
third
year
life
wherea
type
children
younger
year
peak
incid
first
second
year
commonli
associ
croup
laryng
may
also
caus
pneumonia
type
found
hospit
previous
healthi
adult
may
involv
bacteri
pneumonia
infect
occur
young
infant
first
year
life
children
first
two
year
pneumonia
type
seen
primarili
first
month
life
similar
rsv
lower
frequenc
like
rsv
hpiv
reinfect
children
adult
predominantli
mild
respiratori
tract
symptom
accompani
low
short
viru
shed
childhood
cap
parainfluenzaviru
infect
besid
rsv
influenzavirus
common
viral
pathogen
involv
diseas
parainfluenza
viru
infect
report
elderli
pneumonia
case
viral
cap
adult
comorbid
like
copd
chf
character
sever
clinic
outcom
viralbacteri
coinfect
approxim
observ
frequent
ribavirin
vitro
activ
hpiv
aerosol
intraven
ribavirin
use
anecdot
report
reduct
clinic
sign
viral
load
immunocompromis
patient
treatment
start
earli
onset
symptom
ribavirin
resist
viru
variant
describ
rsv
negativestrand
rna
viru
pleomorph
size
nm
diamet
genom
encod
eight
structur
two
nonstructur
protein
helic
capsid
surround
envelop
three
surfac
glycoprotein
fusion
f
protein
mediat
membran
fusion
host
cell
result
viral
penetr
g
protein
respons
attach
host
cell
sh
protein
unknown
function
contrast
paramyxovirus
hemagglutinin
neuraminidas
function
exist
g
protein
highest
degre
antigen
divers
rsv
account
strainspecif
epitop
allow
classif
two
antigen
group
rsva
rsvb
multipl
genotyp
immunolog
import
f
g
glycoprotein
induc
protect
neutral
antibodi
howev
immuneprotect
complet
earli
reinfect
occur
g
glycoprotein
produc
membran
bound
secret
form
secret
form
abl
modul
innat
immun
respons
rsv
prime
protein
increas
sever
ill
rsv
reinfect
children
sever
diseas
caus
rsv
type
thcell
respons
seem
domin
g
protein
induc
unbalanc
thcell
respons
lung
could
result
airway
hyperrespons
mucu
hypersecretionion
inflamm
may
contribut
peripher
blood
pulmonari
eosinophilia
rsv
infect
occur
worldwid
peak
winter
month
temper
climat
raini
season
tropic
climat
b
virus
multipl
variant
gener
circul
simultan
within
epidem
outbreak
yearli
outbreak
possibl
pattern
circul
rsv
strain
chang
depend
local
strainspecif
immun
human
popul
rsv
import
caus
acut
respiratori
tract
viral
infect
infant
primari
infect
symptomat
spectrum
clinic
manifest
mild
upper
tract
ill
lifethreaten
pneumonia
rsv
account
case
pneumonia
first
year
life
peak
incid
rsv
lower
respiratori
tract
infect
lrti
month
age
matern
rsvspecif
antibodi
rapidli
decreas
birth
approxim
month
may
reason
high
frequenc
rsv
infect
month
age
prematur
infant
week
risk
month
birth
children
get
infect
age
year
alreadi
experienc
reinfect
numer
independ
risk
factor
sever
rsv
infect
includ
genet
factor
discuss
immunocompromis
children
rsvrelat
mortal
high
rsv
load
children
primari
immunodefici
immunocompet
adult
younger
year
rsv
reinfect
gener
mild
may
contribut
lower
respiratori
tract
infect
elderli
peopl
reinfect
induc
lifethreaten
pneumon
similar
children
may
exist
specif
risk
factor
sever
rsv
diseas
differ
studi
adult
elderli
patient
develop
rsv
diseas
depend
risk
factor
infect
account
hospit
pneumonia
develop
prophylact
vaccin
rsv
pursu
high
prioriti
formalininactiv
rsv
vaccin
develop
unfortun
led
sever
lung
diseas
vaccin
children
subsequ
rsv
challeng
ribavirin
licens
treat
sever
rsvassoci
diseas
children
immun
globulin
intraven
administr
human
monoclon
antibodi
prepar
palivizumab
synagi
design
prevent
reduc
sever
rsv
infect
shown
rsvinfect
infant
lower
respiratori
tract
diseas
ribavirin
aerosol
therapi
improv
clinic
outcom
may
effect
adult
well
despit
high
dose
prolong
treatment
patient
ribavirinresist
rsv
variant
isol
recent
identifi
paramyxoviru
close
relat
pneumoviru
rsv
hmpv
differ
rsv
two
aspect
lack
nonstructur
protein
differ
gene
constel
hpmv
classifi
two
main
lineag
b
base
sequenc
analys
f
gen
sequenc
analysi
differ
hmpv
gene
includ
g
gene
requir
refin
character
viru
isol
two
major
group
numer
genotyp
cocircul
throughout
year
sometim
even
genet
distinct
strain
hmpv
circul
year
infect
detect
late
winter
earli
spring
follow
peak
activ
rsv
influenzaviru
viru
first
detect
young
children
netherland
serolog
studi
show
viru
circul
human
least
year
hmpv
worldwid
distribut
associ
respiratori
ill
age
group
caus
upper
respiratori
tract
infect
also
associ
lower
respiratori
tract
infect
suggest
sever
hmpv
infect
occur
children
year
age
seem
peak
third
fifth
month
life
somewhat
later
rsv
found
less
frequent
hospit
children
rsv
clinic
cours
may
milder
base
presenc
hmpv
antibodi
approxim
children
age
two
age
year
hmpv
histori
hmpv
like
rsv
may
caus
clinic
import
reinfect
late
childhood
adult
life
highest
infect
rate
found
young
adult
hmpv
also
respons
pneumonia
prematur
born
babi
person
risk
although
studi
maggi
et
al
number
infant
age
less
year
small
major
hmpvinfect
children
develop
pneumonia
incid
studi
higher
report
differ
relat
differ
popul
children
studi
rate
bronchopneumonia
higher
children
isol
hmpv
infect
children
mix
infect
surpris
studi
detect
hmpv
rna
plasma
hmpvinfect
children
like
shown
also
rsv
infect
hmpv
pneumonia
clinic
distinguish
rsv
influenza
diseas
seem
somewhat
less
sever
greater
percentag
case
underli
diseas
compar
influenzaor
rsvassoci
pneumonia
small
studi
demonstr
hmpv
rel
import
viral
pathogen
also
lead
pneumonia
especi
elderli
adult
underli
diseas
like
copd
chf
asthma
addit
studi
need
especi
yearlong
activ
surveil
consecut
year
analysi
data
futur
respiratori
season
fulli
defin
clinic
epidem
impact
hmpv
infect
therapi
resist
antivir
agent
antibodi
prepar
current
avail
treatment
hmpv
infect
shown
ribavirin
polyclon
intraven
immunoglobulin
equival
vitro
activ
hmpv
rsv
treatment
may
consid
sever
hmpv
infect
immunocompromis
patient
report
resist
hmpv
exist
picornavirus
nonenvelop
particl
diamet
nm
small
consist
singl
positivestrand
rna
genom
surround
icosahedr
capsid
compos
protom
protom
consist
three
nonglycosyl
surfac
protein
intern
protein
center
protomer
unit
canyon
antigen
site
structur
found
bind
receptor
target
cell
immunolog
distinct
rhinoviru
serotyp
two
speci
b
distinguish
rhinovirus
acidlabil
differ
membran
receptor
recognit
enteroviru
serotyp
exist
rhinovirus
ubiquit
infect
rel
low
infecti
dose
occur
throughout
year
import
pathogen
common
cold
human
peak
season
late
autumn
rhinovirus
abl
infect
lower
respiratori
tract
shown
experiment
infect
lower
respiratori
infect
rhinovirus
detect
bronchial
biopsi
sampl
common
cold
unusu
picornavirus
frequent
detect
viru
respiratori
tract
infect
first
year
life
hospit
infant
acut
expiratori
wheez
ill
respiratori
picornavirus
rhinoand
enterovirus
found
case
older
children
picornavirus
predomin
age
year
children
older
year
earlier
studi
includ
rhinovirus
current
data
suggest
rare
involv
pneumonia
infant
young
children
older
adult
rhinovirus
caus
pneumonia
children
age
group
month
highest
isol
rate
found
children
month
frequenc
rsv
coinfect
rhinovirus
bacteria
found
pediatr
patient
cap
inflammatori
respons
rhinoviru
infect
strong
sever
cytokin
relat
pneumonia
like
may
import
factor
rhinoviru
pathogenesi
recent
review
enterovirusassoci
respiratori
tract
diseas
rotbart
et
al
report
infect
patient
present
pneumonia
contrast
kellner
et
al
prospect
studi
recov
enterovirus
sporad
children
upper
respiratori
tract
diseas
howev
case
report
exist
fatal
pneumonia
congenit
neonat
echovirusinfect
infant
rare
sporad
case
matern
diseas
report
epidem
outbreak
hand
foot
mouth
diseas
enteroviru
children
observ
cn
involv
pulmonari
edema
appear
use
modern
diagnost
method
increasingli
recogn
rhinoviru
enteroviru
infect
common
reason
unnecessari
antibiot
therapi
promis
antivir
call
win
compound
pleconaril
broad
potent
antiev
antirv
activ
bind
hydrophob
site
base
capsid
canyon
inhibit
uncoat
capsid
enterovirus
rhinovirus
speci
b
signific
reduc
suscept
pleconaril
therapeut
applic
import
differenti
natur
occur
resist
pleconaril
b
rhinovirus
emerg
rv
resist
pleconaril
treatment
pleconaril
shown
effect
experiment
studi
significantli
reduc
clinic
symptom
treat
adult
volunt
avail
life
threaten
enteroviru
infect
immunocompromis
patient
ten
percent
enteroviru
isol
shown
resist
pleconaril
patient
respond
resist
viru
identifi
ruprintrivir
inhibitor
viral
encod
proteas
still
investig
treatment
rhinoviru
infect
immunocompet
patient
hantavirus
envelop
predominantli
negativestrand
rna
virus
ambisens
genom
virus
consist
three
differ
singlestrand
rna
segment
segment
l
encod
viral
polymeras
glycoprotein
process
glycoprotein
locat
envelop
nucleocapsidprotein
viru
particl
spheric
shape
diamet
nm
also
elong
form
seen
nm
hantavirus
import
zoonot
pathogen
primarili
rodent
infect
persist
seem
asymptomat
natur
rodent
host
antibodi
hantavirus
also
present
nonnatur
host
wild
domest
anim
besid
transmiss
human
humanrod
contact
infect
acquir
inhal
viruscontamin
aerosol
rodent
excreta
saliva
urin
fece
occasion
transmiss
may
occur
person
person
document
and
viru
argentina
hantavirus
belong
call
emerg
pathogen
caus
influenzalik
acut
pulmonari
diseas
north
middl
south
america
hantaviru
pulmonari
syndrom
hp
first
hp
recogn
usa
caus
number
hantaviru
variant
eg
sin
nombr
viru
snv
symptom
hp
may
vari
depend
viru
genotyp
case
hp
report
south
america
new
strain
and
hantaviru
identifi
late
earli
first
outbreak
novel
hantaviru
choclo
viru
document
central
america
overal
mortal
declin
consequ
better
recogn
less
sever
form
infect
better
medic
manag
confirm
case
hp
far
includ
children
major
case
adult
year
snv
account
small
number
pediatr
case
us
wherea
and
viru
found
pediatr
patient
chile
south
argentina
higher
proport
incub
period
and
viru
chile
day
febril
prodromi
last
approxim
day
follow
rapid
progress
moder
sever
respiratori
distress
hantaviru
diseas
establish
specif
therapi
current
avail
ribavirin
show
activ
hv
well
document
studi
emerg
resist
hv
unknown
develop
countri
frequent
complic
measl
viru
infect
respons
mortal
rate
measl
viru
infect
caus
transient
strong
immunosuppress
reason
increas
suscept
viral
bacteri
infect
infect
patient
measl
viru
caus
pneumonia
present
either
primari
measl
viru
pneumonia
atyp
measl
viru
pneumonia
patient
develop
secondari
bacteri
pneumonia
measl
pneumonia
rare
occur
young
adult
shown
measl
outbreak
us
air
forc
recruit
respons
case
pneumonia
twothird
secondari
bacteri
infect
pregnanc
measl
viru
infect
induc
higher
number
pneumonia
mother
report
preterm
newborn
infant
measl
pneumonia
observ
primari
infect
herp
virus
abl
persist
lifelong
human
host
typic
latent
infect
also
reactiv
immunosuppress
like
cmv
hsv
vzv
ebv
may
induc
pneumonia
pneumonia
may
occur
occasion
highrisk
person
rare
dissemin
hsv
infect
pregnanc
report
case
previous
healthi
womn
fatal
progress
pneumonia
third
trimest
pregnanc
ramsey
et
al
report
patient
pneumonia
could
differenti
case
focal
hsv
pneumonia
result
hsv
spread
lung
parenchyma
case
interstiti
pneumonia
result
hematogen
dissemin
hsv
immunocompet
adult
primari
vzv
infect
uncommon
incid
increas
vzv
pneumonia
main
complic
incid
high
mortal
patient
may
develop
secondari
bacteri
pneumonia
patient
least
one
known
risk
factor
like
pregnanc
smoke
chronic
obstruct
pulmonari
diseas
vzv
besid
influenzaviru
common
pathogen
caus
pneumonia
pregnanc
predominantli
second
third
trimest
risk
primari
vzv
infect
vzv
pneumonia
pregnanc
higher
patient
smoker
manifest
multipl
skin
lesion
mortal
rate
possibl
antivir
intervent
significantli
higher
pregnanc
versu
vzv
pneumonia
consequ
primari
vzv
infect
childhood
rare
cmvinfect
preterm
infant
develop
chronic
lung
diseas
may
associ
cmv
pneumonia
high
mortal
ganciclovir
treatment
shown
rapidli
improv
symptom
fact
support
cmv
causal
pneumonia
extrem
rare
report
cmv
pneumonia
previous
healthi
adult
patient
lymphoma
cmv
pneumonia
less
common
incid
chemotherapi
corticosteroid
applic
approxim
mortal
rate
two
genet
distinct
variant
exist
primari
infect
variant
domin
primari
infect
sever
respiratori
diseas
extrem
rare
complic
case
report
knox
et
al
fatal
pneumon
due
infect
document
infant
sever
lymphocytopenia
wherea
immunocompromis
patient
bmt
pneumonia
document
immunocompet
patient
etiolog
role
reactiv
infect
pneumonia
clearli
defin
anoth
report
extrem
rare
case
pneumonia
document
merk
et
al
appar
immunocompet
young
women
develop
fatal
pneumonia
mild
asymptomat
pneumon
describ
case
infecti
mononucleosi
sever
pneumon
result
primari
ebv
infect
rare
immunocompet
patient
patient
lymphocyt
interstiti
pneumonia
ebv
dna
found
lung
tissu
infant
children
adult
well
autopsi
case
diffus
interstiti
pneumonia
ebv
dna
could
detect
leukocyt
pneumocyt
frequent
airway
epitheli
cell
ebvassoci
lymphocyt
interstiti
pneumonia
without
hiv
infect
report
predominantli
adult
also
true
rare
chronic
interstiti
lung
diseas
due
ebv
mainli
seen
adult
also
shown
two
infant
earli
month
life
especi
adult
patient
respiratori
viru
infect
extrem
underdiagnos
sinc
adequ
possibl
virolog
diagnosi
routin
perform
diagnosi
acut
respiratori
infect
detect
infecti
virus
viral
compon
protein
nucleic
acid
method
choic
wherea
antibodi
detect
relev
use
select
patient
later
timepoint
infect
use
pair
sera
nasopharyng
aspir
npa
gold
standard
detect
major
respiratori
virus
predominantli
adopt
infant
children
npa
taken
suction
cellcontain
mucos
secret
nasopharyng
area
approxim
ml
fluid
collect
ml
viral
transport
medium
nasal
lavag
obtain
less
discomfort
patient
gentli
instil
ml
pb
room
temperatur
nostril
simultan
suction
steril
trap
sensit
viru
detect
compar
npa
controversi
report
rsv
nasopharyng
swab
taken
usual
adult
obtain
deep
bilater
nasal
posterior
pharynx
swab
steril
cotton
swab
place
ml
viral
transport
medium
vtm
calcium
algin
swab
swab
wooden
stick
may
contain
substanc
inactiv
virus
inhibit
pcr
test
use
tracheal
aspir
collect
intub
patient
instil
ml
steril
normal
salin
endotrach
tube
suction
steril
trap
easili
obtain
specimen
lower
respiratori
tract
patient
induc
sputum
collect
morn
rins
mouth
throat
steril
hyperton
salin
thereaft
sputum
collect
steril
contain
induc
sputum
repres
complet
sampl
respiratori
tract
compar
nasopharyng
aspir
specimen
induc
sputum
might
use
viru
detect
lower
respiratori
tract
oblig
admixtur
saliva
accompani
flora
obviou
disadvantag
nevertheless
minim
saliva
contamin
valuabl
altern
materi
bal
bronchioalveolar
lavag
bal
high
diagnost
yield
infecti
pathogen
predominantli
immunocompromis
patient
lung
infiltr
transbronchi
biopsi
tbb
lung
biopsi
invas
techniqu
addit
bal
significantli
improv
diagnost
yield
edta
blood
immunosuppress
patient
may
facilit
diagnosi
virus
eg
adenoviru
cmv
dissemin
viru
infect
determin
viru
load
may
predict
diseas
outcom
furthermor
viru
load
import
monitor
therapi
enzymeimmunoassay
eia
rapid
viral
antigen
detect
airway
secret
exist
almost
major
respiratori
virus
often
evalu
children
may
vari
sensit
specif
rang
result
eia
detect
singl
respiratori
virus
usual
avail
min
h
altern
screen
respiratori
virus
airway
secret
achiev
indirect
immunofluoresc
antigen
assay
ifa
sensit
specif
use
pool
monoclon
antibodi
whose
specif
direct
rsv
influenzavirus
b
parainfluenzavirus
adenoviru
examin
sever
cell
spot
cytospin
prepar
slide
pool
singl
antisera
allow
viral
antigen
detect
type
within
h
result
strongli
depend
qualiti
clinic
materi
elderli
hospit
immunocompromis
patient
viru
associ
lrti
rapid
virusantigen
detect
insensit
rapid
convent
method
avail
like
coronavirus
metapneumovirus
rhinovirus
enterovirus
pcr
establish
pcr
may
use
altern
mention
antigen
detect
assay
offer
great
sensit
use
wider
rang
viral
pathogen
principl
pcr
detect
differenti
sever
virus
simultan
singl
reaction
mixtur
multipl
rtpcr
multiplex
pcr
provid
lower
sensit
pcr
singl
pathogen
difficult
establish
earli
detect
monitor
viral
infect
quantit
pcr
repres
sensit
techniqu
deliv
result
within
h
diagnosi
dissemin
viru
infect
pulmonari
manifest
frequent
caus
adenovirus
rsv
infant
nonconvent
respiratori
virus
like
cmv
addit
analysi
plasma
edta
blood
help
clinic
specimen
name
secret
respiratori
tract
use
infect
assay
centrifug
enhanc
shell
vial
cultur
svc
inocul
airway
specimen
differ
cell
system
suscept
mani
respiratori
virus
cell
cultur
evalu
earli
viru
infect
h
pool
virusspecif
monoclon
antibodi
afterward
type
respect
individu
monoclon
antibodi
ifa
isol
viru
must
type
preferenti
ifa
use
virusspecif
monoclon
antibodi
otherwis
increasingli
pcr
convent
cell
cultur
viru
isol
impact
clinic
decis
manag
patient
hospit
viru
isol
use
character
viru
strain
involv
epidem
outbreak
serolog
use
acut
phase
infect
due
delay
onset
antibodi
respons
approxim
end
first
week
diseas
serolog
method
detect
antibodi
use
serolog
method
diagnosi
viral
infect
cap
suffici
pair
serum
sampl
may
use
detect
seroconvers
fourfold
increas
antibodi
titer
compar
first
second
serum
serolog
addit
limit
valu
newborn
matern
antibodi
immunocompromis
patient
elderli
patient
receiv
blood
product
antibodi
detect
done
complement
fixat
test
cft
increasingli
obsolet
elisaigg
iga
igm
immunofluoresc
assay
immunoblot
neutral
test
adenoviru
virus
detect
patient
dissemin
infect
peripher
blood
week
detect
viru
multipl
site
correl
sever
diseas
higher
mortal
essenti
monitor
viral
load
antivir
therapi
phenotyp
isol
done
neutral
test
hemagglutin
test
serotypespecif
monoclon
antibodi
final
pcr
groupspecif
antigen
use
cft
antibodi
detect
second
week
diseas
cft
insuffici
detect
antibodi
infant
igg
antibodi
detect
elisa
end
second
week
wherea
igm
antibodi
detect
case
primari
infect
hcov
antigen
detect
ift
use
rabbit
antisera
monoclon
avail
coronavirus
rna
detect
rtpcr
also
stool
sarscov
detect
plasma
urin
stool
longer
week
viru
load
unusu
low
earli
phase
sar
chipbas
test
detect
respiratori
viral
pathogen
includ
coronavirus
develop
nonsar
human
coronavirus
difficult
isol
sarshcov
igg
igm
antibodi
found
within
first
day
diseas
seroconvers
may
delay
week
igg
persist
rapid
antigen
detect
test
avail
min
differenti
b
virus
includ
avian
influenza
viru
sensit
specif
rang
respect
rtpcr
much
sensit
allow
viru
type
viru
isol
still
import
character
circul
influenza
strain
antibodi
detect
elisaigg
iga
ifaigg
iga
possibl
show
low
level
igg
iga
delay
peak
antibodi
titer
shorter
persist
antibodi
elderli
patient
adult
elderli
peopl
viru
shed
lower
shorter
rtpcr
sensit
patient
parainfluenzaviru
rsv
infect
particularli
reinfect
might
use
especi
rapid
diagnosi
elderli
rapid
rsv
antigen
detect
pediatr
patient
differ
antigen
detect
assay
min
sensit
specif
avail
altern
rapid
immunofluoresc
antigen
assay
use
sinc
rsv
thermolabil
import
use
qualifi
transport
medium
cool
short
transport
process
min
shell
vial
cultur
assay
show
highest
sensit
specif
detect
rsv
npa
children
younger
year
rsvinfect
children
could
identifi
serolog
antibodi
titer
develop
usual
low
although
serum
secretori
antibodi
produc
commerci
monoclon
antibodi
avail
ifa
sensit
specif
test
respect
result
agre
rtpcr
isol
hmpv
difficult
regardless
cpe
use
rtpcr
enhanc
hmpv
identif
cell
cultur
indic
commerci
test
avail
antibodi
detect
due
distinct
serotyp
rapid
detect
rhinoviru
capsid
antigen
develop
applic
molecular
assay
markedli
increas
detect
rate
picornavirus
acut
respiratori
infect
rhinoviru
cultur
gold
standard
take
day
sensit
pcr
superior
infect
detect
cell
cultur
reliabl
typespecif
serolog
test
rhinoviru
infect
exist
entervoiru
serolog
neutral
test
possibl
difficult
complet
reliabl
current
antigen
detect
assay
avail
rtpcr
hantaviru
rna
detect
use
detect
infect
identifi
viral
genotyp
rtpcr
viral
rna
detect
done
whole
blood
serum
acut
phase
first
day
ill
viru
isol
ineffici
routin
assay
serum
specimen
test
igm
igg
antibodi
elisa
use
sin
nombr
viru
antigen
accord
guidelin
us
center
diseas
control
cdc
posit
result
indic
infect
new
world
hantavirus
igm
antibodi
detect
acut
case
maxim
igg
level
occur
first
week
ill
detect
diseas
rel
long
period
sinc
hsv
vzv
cmv
pneumonia
effect
treat
import
rapidli
investig
specimen
lower
respiratori
tract
pneumonia
establish
basi
bal
lung
tissu
examin
pcr
hsv
vzv
andor
shell
vial
cultur
hsv
serolog
test
relev
case
hsv
reactiv
primari
vzv
infect
confirm
igm
detect
igg
seroconvers
prematur
infant
risk
cmv
pneumonia
cmv
dna
found
directli
pcr
urin
pharynx
viru
detect
airway
specimen
viru
load
bal
lung
tissu
posit
seronconvers
variou
studi
case
report
shown
respiratori
viral
pathogen
frequent
involv
communityacquir
pneumonia
age
group
risk
young
elderli
well
person
comorbid
immun
respons
restrict
frequenc
detect
respiratori
virus
vari
differ
studi
due
methodolog
problem
patient
select
fact
detect
specif
virus
perform
modern
diagnost
tool
increasingli
realiz
rhinoviru
enteroviru
infect
common
reason
unnecessari
antibiot
therapi
often
also
adenoviru
infect
futur
studi
consid
whole
rang
viral
agent
involv
communityaquir
pneumonia
recent
decad
sever
new
respiratori
virus
describ
reason
assum
new
virus
viru
type
differ
viru
famili
emerg
futur
often
cross
host
speci
barrier
high
pathogen
potenti
sever
pulmonari
diseas
relev
infect
diagnos
viru
detect
sever
studi
children
document
signific
proport
viralbacteri
infect
besid
isol
viru
infect
children
isol
viru
infect
tend
younger
coinfect
children
implic
coinfect
agent
epidemiolog
pathogen
clinic
outcom
elucid
